In this episode, we profile Bristol Myers Squibb (BMS), an American multinational pharmaceutical powerhouse headquartered in Princeton, New Jersey, ranked 94th on the Fortune 500. We trace the company’s lineage back to the 1989 merger of two historic firms: Squibb, a supplier of medical goods to the Union Army during the Civil War, and Bristol-Myers, which once produced consumer goods like Ipana toothpaste and Sal Hepatica. Listeners will learn how the company transformed from a diversified producer into a specialized biopharmaceutical leader, focusing heavily on oncology, cardiovascular diseases, and immunology.

We break down the company's massive financial footprint, noting its $48.3 billion revenue in 2024 driven by top-selling drugs such as the anticoagulant Eliquis and the cancer immunotherapy Opdivo. The episode also explores BMS's ag ...